Johnson & Johnson's Q4 Financial Highlights

Johnson & Johnson (J&J) announced on Wednesday a significant 5.3% increase in total sales for the fourth quarter of fiscal 2024, reaching $22.5 billion. This growth slightly surpassed market expectations, showcasing the company's robust performance amidst challenging economic conditions.

Earnings and Annual Performance

Despite the sales uptick, diluted earnings per share experienced a 17.1% decline year-over-year, settling at $1.41 for the quarter. However, the full-year narrative tells a story of growth, with sales climbing 4.3% to $88.8 billion and net earnings increasing by 5.6% to $14.1 billion. Notably, earnings per share (EPS) saw an impressive 11.3% rise, culminating at $5.79 by the end of fiscal 2024.

Leadership's Perspective

"2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline, and industry-leading investments in innovation," remarked CEO Joaquin Duato, reflecting on the company's achievements and future direction.

Market Reaction

Following the earnings announcement, Johnson & Johnson's stock experienced a 1.75% increase in premarket trading, with shares priced at $148.15 each, signaling investor confidence in the company's trajectory.